Cannell & Spears LLC Acquires 20,678 Shares of IQVIA Holdings Inc. (NYSE:IQV)

Cannell & Spears LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 107.6% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 39,888 shares of the medical research company’s stock after buying an additional 20,678 shares during the period. Cannell & Spears LLC’s holdings in IQVIA were worth $7,838,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Vanguard Group Inc. grew its holdings in IQVIA by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 20,131,734 shares of the medical research company’s stock valued at $3,956,087,000 after purchasing an additional 105,504 shares during the period. Mitsubishi UFJ Asset Management Co. Ltd. increased its position in shares of IQVIA by 2.5% during the 4th quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 2,438,726 shares of the medical research company’s stock worth $481,380,000 after purchasing an additional 59,426 shares during the last quarter. Cantillon Capital Management LLC raised its position in IQVIA by 12.3% during the fourth quarter. Cantillon Capital Management LLC now owns 2,066,144 shares of the medical research company’s stock worth $406,018,000 after acquiring an additional 226,017 shares in the last quarter. JPMorgan Chase & Co. lifted its stake in IQVIA by 46.2% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,845,711 shares of the medical research company’s stock valued at $437,378,000 after purchasing an additional 583,396 shares during the last quarter. Finally, Norges Bank bought a new position in shares of IQVIA during the 4th quarter worth approximately $336,041,000. Institutional investors own 89.62% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on IQV. William Blair reissued an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Robert W. Baird reduced their price objective on IQVIA from $212.00 to $210.00 and set a “neutral” rating on the stock in a research note on Tuesday, January 21st. Barclays dropped their price target on IQVIA from $255.00 to $235.00 and set an “overweight” rating for the company in a research note on Monday, February 3rd. JPMorgan Chase & Co. decreased their price objective on IQVIA from $240.00 to $232.00 and set an “overweight” rating for the company in a report on Tuesday, February 18th. Finally, Truist Financial restated a “buy” rating and issued a $263.00 target price (up previously from $261.00) on shares of IQVIA in a report on Monday, February 10th. Five analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat, IQVIA currently has an average rating of “Moderate Buy” and an average price target of $249.05.

IQVIA Stock Down 1.2 %

Shares of IQVIA stock opened at $177.27 on Monday. The firm’s 50 day moving average price is $193.15 and its 200-day moving average price is $206.05. The company has a market cap of $31.25 billion, a P/E ratio of 23.64, a PEG ratio of 1.99 and a beta of 1.50. The company has a quick ratio of 0.84, a current ratio of 0.84 and a debt-to-equity ratio of 2.12. IQVIA Holdings Inc. has a 52-week low of $176.03 and a 52-week high of $253.84.

IQVIA (NYSE:IQV) last posted its earnings results on Thursday, February 6th. The medical research company reported $2.90 EPS for the quarter, missing the consensus estimate of $3.11 by ($0.21). IQVIA had a return on equity of 28.81% and a net margin of 8.91%. On average, sell-side analysts predict that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.